Synergistic antitumor effect of oroxylin A and donafenib in hepatocellular carcinoma through tumor protein p53 signaling pathway activation

doi:10.3748/wjg.v32.i6.113529

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (54)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series, Tables (1-1) series.

Item

Count

PDF

HTML

Figures (1-7)

Tables (1-1)

Sum=8

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=34

Feb 14, 2026 (publication date) through Feb 5, 2026

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Feb 14, 2026; 32(6): 113529
Published online Feb 14, 2026. doi: 10.3748/wjg.v32.i6.113529

Table 1 the concentration of alanine aminotransferase, aspartate aminotransferase, blood urea nitrogen and creatinine in each group after treatment with oroxylin A and/or donafenib

Index	Treatment	d0	d7	d14	d21
ALT (U/L)	Control	21.02	20.03	25.12	21.75
	Oroxylin A	19.64	19.89	22.84	22.14
	Donafenib	24.14	19.70	21.79	24.58
	Oroxylin A + donafenib	26.87	21.91	21.79	20.00
AST (U/L)	Control	104.83	114.41	107.77	117.92
	Oroxylin A	105.37	115.67	102.81	121.66
	Donafenib	99.10	113.13	101.34	112.74
	Oroxylin A + donafenib	115.21	110.32	111.39	126.61
BUN (μg/mL)	Control	153.75	183.21	142.78	153.50
	Oroxylin A	165.93	182.93	149.81	138.22
	Donafenib	166.48	168.75	148.67	149.67
	Oroxylin A + donafenib	154.05	161.61	154.82	136.39
Cr (μmol/L)	Control	22.90	23.98	28.58	26.99
	Oroxylin A	26.49	21.97	27.01	28.91
	Donafenib	22.00	26.56	28.58	26.72
	Oroxylin A + donafenib	24.40	23.69	29.36	28.64

d0: Before drug treatment; d7: Drug treatment for 7 days; d14: Drug treatment for 14 days; d21: Drug treatment for 21 days; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BUN: Blood urea nitrogen; Cr: Creatinine.

Full Size Table

Citation: Zhang MY, Sun RQ, Min Q, Zhu YQ, Qin SK, Guo QL. Synergistic antitumor effect of oroxylin A and donafenib in hepatocellular carcinoma through tumor protein p53 signaling pathway activation. World J Gastroenterol 2026; 32(6): 113529
URL: https://www.wjgnet.com/1007-9327/full/v32/i6/113529.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i6.113529